Artificial Organ Market

Executive Summary

Artificial Organ Market was valued at US $19.00 billion in 2021 and is projected to grow at 9.22% CAGR over the forecast period to reach US $32.25 billion by 2027. Artificial Organ Market represented US $3.07 billion opportunity over 2019-2021 and estimated to create US $13.25 billion opportunity in 2027 over 2021.

Artificial Organ from Consainsights analyses the Artificial Organ Market in the Life Sciences industry over the forecast period to 2027.

Artificial Organ research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Artificial Organ segmentation includes Organ Type and Geography.

Based on the Organ Type, the Artificial Organ analysis covers Artificial Heart, Artificial Kidney, Artificial Pancreas, Artificial Lungs, Cochlear Implants, Other Organ Types.

In Organ Type segment, Artificial Heart segment has highest cagr growth of 8.15%.

Based on the region, the Artificial Organ analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include B. Braun Melsungen AG, Baxter International Inc., Boston Scientific Corporation, Getinge AB, Medtronic PLC, Abiomed, Asahi Kasei Medical Co. Ltd, Berlin Heart GmbH, Carmat SA, Edward Lifesciences Corporation, Jarvik Heart Inc., Terumo Corporation and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Organ Type

Introduction

In 2021, Artificial Heart segment has the highest revenue of US $7.35 billion and is expected to grow at CAGR of 8.15% by 2027 Artificial Heart segment has highest cagr growth of 8.15%.

Artificial Heart

Artificial Heart segment was valued at US $6.16 billion in 2019 and is projected to grow at 8.15% CAGR over the forecast period to reach US $12.47 billion by 2027. Artificial Heart segment represented US $1.19 billion opportunity over 2019-2021 and estimated to create US $5.12 billion opportunity in 2027 over 2021.

Artificial Kidney

Artificial Kidney segment was valued at US $4.01 billion in 2019 and is projected to grow at 8.15% CAGR over the forecast period to reach US $8.11 billion by 2027. Artificial Kidney segment represented US $0.77 billion opportunity over 2019-2021 and estimated to create US $3.33 billion opportunity in 2027 over 2021.

Artificial Pancreas

Artificial Pancreas segment was valued at US $2.21 billion in 2019 and is projected to grow at 8.15% CAGR over the forecast period to reach US $4.47 billion by 2027. Artificial Pancreas segment represented US $0.43 billion opportunity over 2019-2021 and estimated to create US $1.84 billion opportunity in 2027 over 2021.

Artificial Lungs

Artificial Lungs segment was valued at US $1.85 billion in 2019 and is projected to grow at 8.15% CAGR over the forecast period to reach US $3.74 billion by 2027. Artificial Lungs segment represented US $0.36 billion opportunity over 2019-2021 and estimated to create US $1.54 billion opportunity in 2027 over 2021.

Cochlear Implants

Cochlear Implants segment was valued at US $0.90 billion in 2019 and is projected to grow at 8.15% CAGR over the forecast period to reach US $1.82 billion by 2027. Cochlear Implants segment represented US $0.17 billion opportunity over 2019-2021 and estimated to create US $0.75 billion opportunity in 2027 over 2021.

Other Organ Types

Other Organ Types segment was valued at US $0.81 billion in 2019 and is projected to grow at 8.15% CAGR over the forecast period to reach US $1.64 billion by 2027. Other Organ Types segment represented US $0.16 billion opportunity over 2019-2021 and estimated to create US $0.67 billion opportunity in 2027 over 2021.